NEW YORK (GenomeWeb News) – Berlin-based RiNA has acquired Roche Applied Science's RTS Protein Expression portfolio of cell-free expression kits for an undisclosed sum, Roche said today.
Under the agreement, which takes effect Sept. 15, the firm 5 Prime will serve as RiNA's distributor for the kits, Roche said.
Manfred Baier, who is head of Roche Applied Science, said in a statement that "a company specializing in proteomics will be able to develop the potential of RTS technology much faster than we can."
RiNA, a spin-out from the Institute of Biochemistry at the Free University of Berlin, had previously partnered with Roche. The firm was involved in the development of the RTS technology and has conducted "major research and development activities in the field of prokaryotic and eukaryotic protein expression systems," Roche said.
"Together with 5 PRIME products for purifying and detecting recombinant proteins, RTS technology will form a strong basis for joint development of innovative products in this dynamic field," RiNA CEO Leo Tristram said.
Financial terms of the agreement were not released.